Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462283 | 0.83 | ALDH1A1 (0.50) | CYP1A2ALDH1A1LMNARAPGEF4L3MBTL1 | |
| SCHEMBL11058857 | 0.82 | ALDH1A1 (0.41) | GAAMAPTALDH1A1LMNANOX1 | |
| SCHEMBL11918917 | 0.79 | ALDH1A1 (0.56) | CYP1A2MAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL11878619 | 0.79 | RAPGEF4 (0.41) | GAAMAPTALDH1A1LMNANOX1 | |
| SCHEMBL18550697 | 0.79 | L3MBTL1 (0.40) | GAACYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL6929125 | 0.79 | GAA (0.70) | GAAMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL4620484 | 0.78 | ALDH1A1 (0.45) | GAAMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL11919007 | 0.76 | FFAR4 (0.41) | CYP1A2MAPTALDH1A1ALOX12KMT2A | |
| SCHEMBL11655477 | 0.75 | CYP1A2 (0.44) | GAACYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL2243625 | 0.75 | GAA (0.70) | GAAMAPTALDH1A1LMNANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108369222-B | Opioid receptor modulators and uses thereof | 明尼苏达大学董事会 | 2021-06-04 | — | — | CN | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | Regents of the University of Minnesota (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | OPRM1, OPRK1, OPRL1 | GAA 3118/4885CYP1A2 425/4885MAPT 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.